ArticleClinical cancer research : an official journal of the American Association for Cancer Research2009
Association of MDM2 SNP309, age of onset, and gender in cutaneous melanoma.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.
- Associations of MDM2 rs2279744 and TP53 rs1042522 polymorphisms with cervical cancer risk: A meta-analysis and systematic review.Frontiers in oncology · 2022Pooled it
- MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer.Scientific reports · 2016Trial
- Review
- Sex-Specific Associations ofCancers · 2023Article
- Let's talk about sex: A biological variable in immune response against melanoma.Pigment cell & melanoma research · 2022Review
- The complementary effect of rs1042522 inOncology letters · 2019Article
- Common genetic variants in the TP53 pathway and their impact on cancer.Journal of molecular cell biology · 2019Review
- Adrenal mass of unusual etiology: Ewing sarcoma in a young man.Radiology case reports · 2017Article
- MDM2 gene polymorphisms and risk of classic Kaposi's sarcoma among Iranian patients.Medical microbiology and immunology · 2017Article
- Intratumoral and Peritumoral Mast Cells in Malignant Melanoma: An Immunohistochemical Study.Advanced biomedical research · 2017Article
- An integrative view on sex differences in brain tumors.Cellular and molecular life sciences : CMLS · 2015Review
- Article
- Targeting MDM2-p53 interaction for cancer therapy: are we there yet?Current medicinal chemistry · 2014Review
- Investigation of the effect of MDM2 SNP309 and TP53 Arg72Pro polymorphisms on the age of onset of cutaneous melanoma.The Journal of investigative dermatology · 2012Article
- The relationship between MDM2 expression and tumor thickness and invasion in primary cutaneous malignant melanoma.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2012Article
- Article
- Melanoma in adolescents and young adults (ages 15-39 years): United States, 1999-2006.Journal of the American Academy of Dermatology · 2011Article
- Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck.Molecular carcinogenesis · 2011Article
- B7-H1-dependent sex-related differences in tumor immunity and immunotherapy responses.Journal of immunology (Baltimore, Md. : 1950) · 2010Article
- Single-nucleotide polymorphisms in the p53 signaling pathway.Cold Spring Harbor perspectives in biology · 2010Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 3 institutions in 2 countries.
Funding
Abstract
purposeIn certain cancers, MDM2 SNP309 has been associated with early tumor onset in women. In melanoma, incidence rates are higher in women than in men among individuals less than 40 years of age, but among those older than 50 years of age, melanoma is more frequent in men than in women. To investigate this difference, we examined the association among MDM2 SNP309, age at diagnosis, and gender among melanoma patients. EXPERIMENTAL
designProspectively enrolled melanoma patients (N = 227) were evaluated for MDM2 SNP309 and the related polymorphism, p53 Arg72Pro. DNA was isolated from patient blood samples, and genotypes were analyzed by PCR-restriction fragment length polymorphism. Associations among MDM2 SNP309, p53 Arg72Pro, age at diagnosis, and clinicopathologic features of melanoma were analyzed.
resultsThe median age at diagnosis was 13 years earlier among women with a SNP309 GG genotype (46 years) compared with women with TG+TT genotypes (59 years; P = 0.19). Analyses using age dichotomized at each decade indicated that women with a GG genotype had significantly higher risks of being diagnosed with melanoma at ages <50 years compared with women >or=50 years, but not when the comparison was made between women <60 and >or=60 years. At ages <50 years, women with a GG genotype had a 3.89 times greater chance of being diagnosed compared with women with TG+TT genotypes (P = 0.01). Similar observations were not seen among men.
conclusionsOur data suggest that MDM2 may play an important role in the development of melanoma in women. The MDM2 SNP309 genotype may help identify women at risk of developing melanoma at a young age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.